The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non–Small-Cell Lung Cancer: A Multicenter Phase II Trial
Open accessAbstract
Purpose: A multicenter, phase II trial investigated the efficacy and toxicity of neoadjuvant docetaxel-cisplatin in locally advanced non–small-cell lung cancer (NSCLC) and examined prognostic factors for patients not benefiting from surgery. Patients and Methods: Ninety patients with previously untreated, potentially operable stage IIIA (mediastinoscopically pN2) NSCLC received three cycles of docetaxel 85 mg/m 2 day 1 plus cisplatin 40 mg/m 2 days 1 and 2, with subsequent surgical resection. Results: Administered dose-intensities were docetaxel 85 mg/m 2/3 weeks (range, 53 to 96) and cisplatin 95 mg/m 2/3 weeks (range, 0 to 104). The 265 cycles were well tolerated, and the overall response rate was 66% (95% confidence interval [CI], 55% to 75%). Seventy-five patients underwent tumor resection with positive resection margin and involvement of the uppermost mediastinal lymph node in 16% and 35% of patients, respectively (perioperative mortality, 3%; morbidity, 17%). Pathologic complete response occurred in 19% of patients with tumor resection. In patients with tumor resection, downstaging to N0–1 at surgery was prognostic and significantly prolonged event-free survival (EFS) and overall survival (OS; P = .0001). At median follow-up of 32 months, the median EFS and OS were 14.8 months (range, 2.4 to 53.4) and 33 months (range, 2.4 to 53.4), respectively. Local relapse occurred in 27% of patients with tumor resection, with distant metastases in 37%. Multivariate analyses identified mediastinal clearance (hazard ratio, 0.22; P = .0003) and complete resection (hazard ratio, 0.26; P = .0006) as strongly prognostic for increased survival. Conclusion: Neoadjuvant docetaxel-cisplatin is effective and tolerable in stage IIIA pN2 NSCLC. Resection is recommended only for patients with mediastinal downstaging after chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Rosell, R., Gomez-Codina, J., Camps, C., Maestre, J., Padille, J., Canto, A., Mate, J. L., Li, S., Roig, J., Olazabal, A., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401203300301 · Cited by 1,261
Roth, J. A., Fossella, F., Komaki, R., Ryan, M. B., Putnam, J. B., Lee, J. S., Dhingra, H., De Caro, L., Chasen, M., McGavran, M., et al. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.9.673 · Cited by 1,111
Albain, K. S., Rusch, V. W., Crowley, J. J., Rice, T. W., Turrisi, A. T., Weick, J. K., Lonchyna, V. A., Presant, C. A., McKenna, R. J., & Gandara, D. R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.1880 · Cited by 856
Martini, N., Kris, M. G., Flehinger, B. J., Gralla, R. J., Bains, M. S., Burt, M. E., Heelan, R., McCormack, P. M., Pisters, K. M. W., Rigas, J. R., et al. (1993) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(93)91072-u · Cited by 373
Georgoulias, V, Papadakis, E., Alexopoulos, A., Tsiafaki, X., Rapti, A., Veslemes, M., Palamidas, P., & Vlachonikolis, I. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04644-4 · Cited by 346
Randomized trial of neoadjuvant therapy for lung cancer: Interim analysis
Pass, H. I., Pogrebniak, H. W., Steinberg, S. M., Mulshine, J., & Minna, J. (1992) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(92)90373-c · Cited by 331
Eberhardt, W., Wilke, H., Stamatis, G., Stuschke, M., Harstrick, A., Menker, H., Krause, B., Müeller, M. R., Stahl, M., Flasshove, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.622 · Cited by 328
Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy
Martin, J., Ginsberg, R. J., Abolhoda, A., Bains, M. S., Downey, R. J., Korst, R. J., Weigel, T. L., Kris, M. G., Venkatraman, E. S., & Rusch, V. W. (2001) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(01)02995-2 · Cited by 305
Cited by
van Meerbeeck, J. P., Kramer, G. W. P. M., Van Schil, P. E. Y., Legrand, C., Smit, E. F., Schramel, F., Tjan-Heijnen, V. C., Biesma, B., Debruyne, C., van Zandwijk, N., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk093 · Cited by 705
Hellmann, M. D., Chaft, J. E., William, W. N., Rusch, V., Pisters, K. M. W., Kalhor, N., Pataer, A., Travis, W. D., Swisher, S. G., & Kris, M. G. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70334-6 · Cited by 646
Shu, C. A., Gainor, J. F., Awad, M. M., Chiuzan, C., Grigg, C. M., Pabani, A., Garofano, R. F., Stoopler, M. B., Cheng, S. K., White, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30140-6 · Cited by 623
ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer
De Leyn, P., Lardinois, D., Van Schil, P. E., Rami-Porta, R., Passlick, B., Zielinski, M., Waller, D. A., Lerut, T., & Weder, W. (2007) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2007.01.075 · Cited by 494
Self-citationTravis, W. D., Dacic, S., Wistuba, I., Sholl, L., Adusumilli, P., Bubendorf, L., Bunn, P., Cascone, T., Chaft, J., Chen, G., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.005 · Cited by 465
Self-citation
Metadata
- Authors
- Betticher, D. C., Hsu Schmitz, S.-F., Tötsch, M., Hansen, E., Joss, C., von Briel, C., Schmid, R. A., Pless, M., Habicht, J., Roth, A. D., Spiliopoulos, A., Stahel, R., Weder, W., Stupp, R., Egli, F., Furrer, M., Honegger, H., Wernli, M., Cerny, T., & Ris, H.-B.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-05-01
- Volume
- 21
- Issue
- 9
- Pages
- 1752-1759
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2097049917
- Cited by
- 449
- References
- 18
- FWCI
- 24.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non–Small-Cell Lung Cancer: A Multicenter Phase II Trial. https://app.cochat.ai/papers/10.1200/jco.2003.11.040
- The paper
- Betticher, D. C., Hsu Schmitz, S.-F., Tötsch, M., Hansen, E., Joss, C., von Briel, C., Schmid, R. A., Pless, M., Habicht, J., Roth, A. D., Spiliopoulos, A., Stahel, R., Weder, W., Stupp, R., Egli, F., Furrer, M., Honegger, H., Wernli, M., Cerny, T., & Ris, H.-B. (2003). Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non–Small-Cell Lung Cancer: A Multicenter Phase II Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2003.11.040
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.